User:Mr. Ibrahem/Ravulizumab

Ravulizumab, sold under the brand name Ultomiris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is given by gradual injection into a vein.

Common side effects include upper respiratory tract infection, diarrhea, fever, nausea, and headache. Other side effect may include meningococcal infection. While there is no clear harm in pregnancy, such use has not been well studied. It is a monoclonal antibody that bind to and blocks the activity of complement component 5 (C5).

Ravulizumab was approved for medical use in the United States in 2018 and Europe in 2019. In the United States it costs about 460,000 USD per year as of 2019.